MYGN Myriad Genetics Inc.

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Management will also participate in two upcoming healthcare conferences

SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes.  

During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2023. Revenue and earnings guidance for 2024 will also be shared.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at . To participate in the live conference call via telephone, please . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. Following the conference call, an archived webcast of the call will be available at .

March Investor Conferences

Management will also be participating in the following investor conferences:

  • The 45th Annual Raymond James & Associates Institutional Investors Conference with a presentation from Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, on March 4, 2024, at 4:35pm EST.
  • The 44th Annual Cowen Health Care Conference with a fireside chat featuring Sam Raha, chief operating officer, and Ben Wheeler, chief financial officer – operations, on March 5, 2024, at 12:50pm EST.

A live and archived webcast of both presentations can be viewed in the investor relations section of Myriad’s website at  .

About Myriad Genetics 

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .   

Investor Contact

Matt Scalo

(801) 584-3532

Media Contact

Glenn Farrell

(385) 318-3718



EN
21/02/2024

Underlying

MYGNMyriad Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE
Free
MYGN Myriad Genetics...

New Study Published in JCO Precision Oncology Shows Myriad Genetics' P...

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation t...

13h / 46m 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; A...

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year period, reflecting no-pay reduction efforts.First quarter GAAP net loss of $26 million and positive adjusted EBITDA of $4 million; net loss and adjusted EBITDA improve...

May 7, 2024 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Announces Reorganization of European Operations and Sa...

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States. As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro med...

May 7, 2024 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics to Release First Quarter 2024 Financial Results on May...

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 Management will also participate in four upcoming investor healthcare conferences SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first...

April 30, 2024 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to P...

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor 80% of people diagnosed with anxiety, depression report losing years or decades of time SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest Mental Health Monitor, a nationwide survey from , Inc. (NASDAQ:MYGN), a leader in genetic testing and precis...

April 17, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch